Navigation Links
Federal Byetta, Victoza, Januvia Lawsuits Could See Consolidation This Month, Rottenstein Law Group LLP Reports
Date:7/10/2013

(PRWEB) July 10, 2013

On July 25 a judicial panel will consider the consolidation of federal Byetta, Januvia and Victoza lawsuits for pretrial purposes, according to court documents in In RE: Incretin Mimetics Products Liability Litigation (MDL-2452; U.S. Judicial Panel on Multidistrict Litigation). The Rottenstein Law Group LLP, a law firm that represents clients in Byetta, Victoza and Januvia lawsuits, explains the importance of this decision.

The three drugs each are designed to treat type-2 diabetes. The plaintiffs in the cases for the drugs all have common cause for suit, alleging that they suffered the same potentially dangerous side effects, according to court documents.

A March 2013 announcement* by the U.S. Food and Drug Administration mentioned findings similar to the allegations of the plaintiffs: That the drugs caused inflammation of the pancreas and pre-cancerous changes to the cells of the pancreas. Bristol-Myers Squibb subsidiary Amylin Pharmaceuticals makes Byetta, Merck Januvia and Novo Nordisk Victoza. Byetta and Januvia were also found to potentially increase the risk of thyroid cancer, according to the FDA, though the drugs’ labels did not notify patients of this alleged adverse side effect.**

“A multidistrict consolidation of the lawsuits involving the three drugs would benefit the plaintiffs because it could potentially improve efficiency in time-consuming, costly proceedings such as discovery,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “It reduces, or even eliminates, duplication of efforts.”

The Rottenstein Law Group LLP encourages those who believe they have suffered from the alleged adverse side effects of Byetta, Januvia and Victoza to visit its FAQ page for quick answers to their questions about the drugs, their side effects and lawsuits. If there are additional questions, those looking for more information can use the contact form to get in touch with an attorney.

*fda.gov/Drugs/DrugSafety/ucm343187.htm
**fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190406.htm

About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com

                            ###

Read the full story at http://www.prweb.com/releases/januvia-lawsuits/pancreatic-cancer/prweb10913120.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Stryker Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuances of First Pretrial Order in Federal Stryker Hip Recall Litigation
2. ATA Hosts DC Summit on Federal Telemedicine and mHealth Policy
3. Bernstein Liebhard LLP Notes Plaintiffs’ Opposition to Defense Motion in Federal Litigation of DePuy Pinnacle Lawsuit Claims
4. Employers Are Choosing Orriant to Lower Overall Employee Healthcare Costs and Benefit from Federal Wellness Program Incentives
5. Mirena IUD Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming Case Management Conference in Federal Mirena Side Effects Litigation
6. Actos Lawsuits Move Forward, as Bernstein Liebhard LLP Reports on Recent Status Conference in Federal Actos Bladder Cancer Litigation
7. Federal Data Services Hub Does Exist, AISHealth.com Blog Post Reports
8. New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations
9. Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation
10. Federal Bar Association Chooses Marketing General Incorporated To Manage Mailing Lists
11. Biomet Hip Lawsuits Mount in Federal Biomet M2a Magnum Hip Replacement Litigation, Bernstein Liebhard LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology: